What does REMED PHARMA do?

REMED PHARMA is a wholesaler in Sint-Genesius-Rode. Public Limited, started on 18 November 1996, 2 establishments.

What is the address of REMED PHARMA?

The registered office of REMED PHARMA is located at Bevrijdingslaan 86, 1640 Sint-Genesius-Rode.

Is REMED PHARMA still active?

No. The CBE lists REMED PHARMA with legal situation “Opening faillissement”. The date of the court ruling is published in the Belgian Official Gazette; the register does not carry it.

Is REMED PHARMA registered on Peppol?

No, REMED PHARMA is currently not registered on the Peppol network.

What is the enterprise number of REMED PHARMA?

The enterprise number of REMED PHARMA is BE0459204532.

When was REMED PHARMA founded?

REMED PHARMA was founded on 18 November 1996.

Who are the directors of REMED PHARMA?

According to the 2023 annual accounts, the directors of REMED PHARMA are: TIZIANO RUTILO , Monica Isabelle GOMES FERNADES.

Is REMED PHARMA a reliable company?

Databakkes does not pass judgement; this is what the sources say: Opening faillissement according to the CBE, started on 18 November 1996; 3 annual accounts filed, latest fiscal year 2023; 2 directors known from the annual account; 2 establishments in the CBE.

How much profit did REMED PHARMA make in 2023?

REMED PHARMA recorded a loss after taxes of € 175,571 in financial year 2023.

What is the revenue of REMED PHARMA?

As a small company, REMED PHARMA is not required to publish revenue in its annual accounts. In financial year 2023, its added value was € -179,960.

REMED PHARMA (Public Limited) - Sint-Genesius-Rode

Dossier REMED PHARMA, printed on 30 October 2026 from databakkes.be/en/0459204532/remed-pharma. Sources: CBE, National Bank of Belgium, Belgian Official Gazette.

Warning lights

Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.

Negative equity NBB

More debt than assets in 2 of the last 3 fiscal years.
Two loss years in a row NBB

Negative result in 2022 and 2023.
Tight liquidity NBB

Cash and receivables cover 49 % of short-term debt in 2023; threshold 65 %.
Figures corrected NBB

Corrected annual account filed for 2021.
Legal situation KBO

Opening faillissement according to the CBE.

Financials

Financial year 2023

REMED PHARMA from Sint-Genesius-Rode, company number BE0459204532, closed financial year 2023 with a result of € -175,571 after tax. For that financial year REMED PHARMA recorded a gross margin of € -179,960 and equity of € -184,248. Compared with financial year 2022, the result moved from € -420,755 to € -175,571. The company made a loss. More debts than assets. High debts against a small own buffer. The most recent annual accounts were filed with the National Bank of Belgium on August 30, 2024.

What it is worth Caution

€ -184,248

▼ € 175,571 vs 2022

Assets minus debts, by the books. What is left if everything were sold and paid today.

Loss Caution

€ -175,571

▲ 58 % less loss than in 2022

Profit after tax over the fiscal year.

Cash in the bank

€ 167,692

▲ 11% vs 2022

Cash and bank balances on the last day of the fiscal year.

Where the profit goes Caution

Loss, nothing to pay out

Reserves fell to € -584,498.

People and assets in 2023

Wage cost

€ 38,831

▲ 10% vs 2022

Payroll staff only. What the director pays themselves is already netted into the gross margin and is not shown separately in the accounts.

Debts at end 2023

Bank debt

€ 315,084

▲ 75% vs 2022

Loans from banks and other lenders, long and short.

Owed to suppliers

€ 62,881

▼ 11% vs 2022

Supplier invoices still open on the last day of the fiscal year.

Taxes and wages

€ 4,098

▼ 27% vs 2022

Taxes, VAT and social contributions still to pay.

Key figures per fiscal year Download key figures (CSV)
	2021	2022	2023	Change 2022 → 2023
Gross margin	€ -195,109 Gross margin 2021: € -195,109 First fiscal year in the series	€ -51,707 Gross margin 2022: € -51,707 ▲ € 143,402 vs 2021 (€ -195,109) Favourable step	€ -179,960 Gross margin 2023: € -179,960 ▼ € 128,253 vs 2022 (€ -51,707) Unfavourable step	▼ € 128,253
Profit after taxes	€ -302,677 Profit after taxes 2021: € -302,677 First fiscal year in the series	€ -420,755 Profit after taxes 2022: € -420,755 ▼ € 118,078 vs 2021 (€ -302,677) Unfavourable step	€ -175,571 Profit after taxes 2023: € -175,571 ▲ € 245,185 vs 2022 (€ -420,755) Favourable step	▲ € 245,185
Equity	€ 412,078 Equity 2021: € 412,078 First fiscal year in the series	€ -8,677 Equity 2022: € -8,677 ▼ € 420,755 vs 2021 (€ 412,078) Unfavourable step	€ -184,248 Equity 2023: € -184,248 ▼ € 175,571 vs 2022 (€ -8,677) Unfavourable step	▼ € 175,571
Total debts	€ 367,321 Total debts 2021: € 367,321 First fiscal year in the series	€ 275,962 Total debts 2022: € 275,962 ▼ 25% vs 2021 (€ 367,321) Favourable step	€ 448,895 Total debts 2023: € 448,895 ▲ 63% vs 2022 (€ 275,962) Unfavourable step	▲ 63%
Cash	€ 209,880 Cash 2021: € 209,880 First fiscal year in the series	€ 151,458 Cash 2022: € 151,458 ▼ 28% vs 2021 (€ 209,880) Unfavourable step	€ 167,692 Cash 2023: € 167,692 ▲ 11% vs 2022 (€ 151,458) Favourable step	▲ 11%
Retained profit	€ 11,828 Retained profit 2021: € 11,828 First fiscal year in the series	€ -408,927 Retained profit 2022: € -408,927 ▼ € 420,755 vs 2021 (€ 11,828) Unfavourable step	€ -584,498 Retained profit 2023: € -584,498 ▼ € 175,571 vs 2022 (€ -408,927) Unfavourable step	▼ € 175,571
Bank debt	€ 306,927 Bank debt 2021: € 306,927 First fiscal year in the series	€ 180,302 Bank debt 2022: € 180,302 ▼ 41% vs 2021 (€ 306,927) Favourable step	€ 315,084 Bank debt 2023: € 315,084 ▲ 75% vs 2022 (€ 180,302) Unfavourable step	▲ 75%
Balance sheet total	€ 779,399 Balance sheet total 2021: € 779,399 First fiscal year in the series	€ 267,285 Balance sheet total 2022: € 267,285 ▼ 66% vs 2021 (€ 779,399) Unchanged	€ 264,648 Balance sheet total 2023: € 264,648 ▼ 1% vs 2022 (€ 267,285) Unchanged	▼ 1%
Employees (FTE)	-	0.8 Employees (FTE) 2022: 0.8 First fiscal year in the series	-

Key figures of REMED PHARMA, fiscal years 2021 to 2023, from the annual accounts filed with the National Bank of Belgium.The annual account for fiscal year 2024 has not been filed yet; it was expected before 31 July 2025.

What happened to REMED PHARMA?

What happened at REMED PHARMA in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:

REMED PHARMA is active according to the CBE. Legal situation: Opening faillissement.

Aug 30, 2024 New annual accounts for financial year 2023: loss of € 175,571. filed late Source: NBB ↗
2023 TIZIANO RUTILO became a director. NBB
Oct 1, 2018 New establishment in Wemmel. KBO
2018 Monica Isabelle GOMES FERNADES became a director. NBB
Nov 21, 1996 New establishment in Sint-Genesius-Rode. KBO
Nov 18, 1996 Start of the company according to the CBE. KBO

In short

From € 302,677 loss in 2021 to € 175,571 loss in 2023.

Original PDFs at the National Bank ↗

Management

TIZIANO RUTILO Monica Isabelle GOMES FERNADES

REMED PHARMA

GMG OFFICE

Behind REMED PHARMA are TIZIANO RUTILO and Monica Isabelle GOMES FERNADES. Monica Isabelle GOMES FERNADES is also behind GMG OFFICE.

Directors

According to the 2023 annual accounts

TIZIANO RUTILO

Director

since 2023

Monica Isabelle GOMES FERNADES

Managing director

Also active at: GMG OFFICE

since 2018

Establishments

Establishment units

Physical locations of this company

Registered office

Bevrijdingslaan 86

1640 Sint-Genesius-Rode

2.282.001.808

Kam 56

1780 Wemmel

Active since 1 October 2018

Who else lives here?

A building full of entrepreneurs or one very busy letterbox? Another 1 companies are registered at this address.

All companies at this address →

PERFECTA

€ 76,187 gross margin · 2024

What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.

Details

Company number

0459.204.532

VAT number

BE 0459.204.532

Registered office

Bevrijdingslaan 86, 1640 Sint-Genesius-Rode

Names & denominations

REMED PHARMA · RMD

Enterprise type

Rechtspersoon

Legal form

Public limited company

Legal situation

Opening faillissement

Start date

18 November 1996

Peppol

Not registered

Contact

remedpharma.be [email protected] 02/370.47.33

Activities · NACE

Groothandel in farmaceutische en medische artikelen

Groothandel in farmaceutische producten

View on CBE Public ↗ Annual accounts (NBB) ↗